Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
15.00
-0.07 (-0.46%)
At close: Feb 18, 2026, 4:00 PM EST
14.84
-0.16 (-1.07%)
After-hours: Feb 18, 2026, 7:49 PM EST
Avalo Therapeutics Revenue
In the year 2024, Avalo Therapeutics had annual revenue of $441.00K, down -77.08%.
Revenue (ttm)
$441.00K
Revenue Growth
-77.08%
P/S Ratio
1,446.31
Revenue / Employee
$8,348
Employees
23
Market Cap
277.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 441.00K | -1.48M | -77.08% |
| Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
| Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
| Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
| Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
| Dec 31, 2019 | 6.75M | -278.03K | -3.96% |
| Dec 31, 2018 | 7.03M | -20.78M | -74.73% |
| Dec 31, 2017 | 27.81M | 26.66M | 2,312.27% |
| Dec 31, 2016 | 1.15M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 82.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 82.55M |
| X4 Pharmaceuticals | 33.98M |
| Opus Genetics | 14.63M |
| AC Immune | 5.48M |
| Neurogene | 925.00K |
| Abeona Therapeutics | 400.00K |
AVTX News
- 8 hours ago - Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Benzinga
- 3 months ago - Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - GlobeNewsWire
- 5 months ago - Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources - GlobeNewsWire
- 5 months ago - Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewsWire
- 6 months ago - Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results - Seeking Alpha